In one paragraphArticle in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
28 authors.
Chikashi YanoDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0009-0002-1468-3415 Masahiro AndoDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-6187-9042 Yujiro HiguchiDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Jun-Hui YuanDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-3808-7813 Akiko YoshimuraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-1768-3181 Takahiro HobaraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0009-0001-2900-182X Risa NagatomoDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0009-0009-8800-2994 Fumikazu KojimaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0009-0004-7867-2285 Yu HiramatsuDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-1217-0870 Satoshi NozumaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-4909-7769 Tomonori NakamuraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-4618-9369 Yusuke SakiyamaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0003-0691-1705 Chika MatsuokaDepartment of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Toru YamashitaDepartment of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.ORCID 0000-0003-3634-5679 Takashi KimuraDepartment of Neurology, Hyogo Medical University, Hyogo, Japan.
Ayako MiyazakiDepartment of Clinical Genetics, Hyogo Medical University, Hyogo, Japan.
Chinatsu KinjoDepartment of Clinical Genetics, Hyogo Medical University, Hyogo, Japan.
Kenji YokochiDepartment of Pediatrics, Toyohashi Municipal Hospital, Aichi, Japan.
Nanami YamanakaDepartment of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.ORCID 0009-0007-5017-8711 Nozomu MatsudaDepartment of Neurology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yoshiyuki HanaokaDepartment of Pediatrics, Kurashiki Central Hospital, Okayama, Japan.
Haruka KojimaDepartment of Neurology, Tokyo Women's Medical University, Tokyo, Japan.
Hiroyuki IshiuraDepartment of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.ORCID 0000-0003-2975-7309 Jun MitsuiDepartment of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7425-4765 Shoji TsujiDepartment of Neurology, The University of Tokyo Hospital, Tokyo, Japan.
Hiroshi TakashimaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0003-0989-6141 Funding
Japan Agency for Medical Research and Development 201442014AJapan Agency for Medical Research and Development 201442071AJapan Society for the Promotion of Science London JP18H02742Japan Society for the Promotion of Science London JP20K16604Japan Society for the Promotion of Science London JP21H02842Japan Society for the Promotion of Science London JP21K15702Japan Society for the Promotion of Science London JP22K07495Japan Society for the Promotion of Science London JP22K07519Japan Society for the Promotion of Science London JP22K15713Japan Society for the Promotion of Science London JP23K06931Japan Society for the Promotion of Science London JP23K06966Japan Society for the Promotion of Science London JP24K18708Ministry of Health, Welfare and Labour of Japan 2016100002B
6 · The paper itselfAbstract
backgroundINF2 mutations cause focal segmental glomerulosclerosis (FSGS) and Charcot-Marie-Tooth disease (CMT). Accurate genetic diagnosis is critical, as INF2-related FSGS is typically resistant to immunotherapy yet rarely recurs after transplantation, and its associated neuropathy can mimic treatable immune-mediated disorders such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
methodsWe performed a multicenter study investigating 3329 Japanese patients with inherited peripheral neuropathies/CMT who underwent gene panel sequencing or whole-exome analysis between 2007 and 2024. Clinical data, including electrophysiological assessments, were obtained from the patients' medical records.
resultsWe identified six pathogenic INF2 variants in eight patients, all of which were located within the diaphanous inhibitory domain. Structural modeling revealed clustering of variants near the diaphanous autoregulatory domain-binding pocket, which is critical for INF2 autoinhibition. Clinically, all cases were sporadic, with a median age at neurological onset of 9 years. All patients exhibited lower limb weakness, and 6/8 (75%) had sensory disturbances. All patients also developed kidney dysfunction, with 7/8 (88%) progressing to end-stage renal disease at a median age of 15 years. Furthermore, all patients showed demyelinating neuropathy, and 2/8 (25%) received immunotherapy due to suspected immune-mediated neuropathy.
conclusionAlthough INF2 variants are a rare cause of CMT in Japan, they should be considered in pediatric patients with demyelinating neuropathy and early-onset proteinuria, even in the absence of a family history. Blood and urine tests assessing renal dysfunction can provide guidance for appropriate genetic testing.
Indexed as
Charcot-Marie-Tooth DiseaseForminsGlomerulosclerosis, Focal SegmentalAdolescentAdultChildChild, PreschoolCohort StudiesEast Asian PeopleFemaleHumansJapanMaleMiddle AgedMutationYoung AdultForminsINF2 protein, humanCharcot‐Marie‐Tooth diseasefocal segmental glomerulosclerosisINF2inherited peripheral neuropathiesneuropathy
Identifiers
PMID40985697
PMCPMC12790156
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390